Abstract
In this observational study, the authors retrospectively evaluated outcomes among a cohort of 620 patients who underwent robotic-assisted radical prostatectomy, 105 of which continued their baseline antiplatelet therapy/anticoagulation (AC). The explicit intent of the study was to determine any differential risk of complications posed to those patients who remained on AC perioperatively. No significant difference was identified between the 2 groups with respect to acute intraoperative/postoperative bleeding complications, postoperative thrombotic events, or 90-day overall complication rates.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call